Recent Updates
Recently added Catalysts
CRIS Neutral Sentiment

Duke University Medical Center, Duke Cancer Center

Wednesday, October 23, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article provides an overview of Duke University Medical Center and Duke Cancer Center, detailing their management structure, collaborations, patient studies, and pipeline of drugs. It highlights various ongoing studies such as TakeAim Lymphoma and TakeAim Leukemia, along with information on their scientific resources and investor relations. The content is primarily informational without any specific news or developments.
Price reaction · baseline $109 (2024-10-22 close) · hit pre-market · 20 other CRIS headline(s) in the window, move may be shared
day 0 close · peak
-4.2%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Emavusertib
Phase 2 · Chronic Lymphocytic Leukemia

Full Press Release Details

• About Company Overview Management Board of Directors Advisory Boards
• Collaborations Partner Collaborations Scientific & Research Collaborations
• Patients Patients Overview Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Understanding Primary CNS Lymphoma Compassionate Use Policy
• Pipeline Pipeline Overview Emavusertib (CA-4948) Fimepinostat CA-170 CA-327
• Scientific Resources
• Investors Overview Press Releases Events and Presentations Corporate Governance Committee Composition Contact the Board Financial Information SEC Filings Annual Reports IRS Form 8937 Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage Contact Us
• Careers Life at Curis Open Positions Benefits
• Contact
• Company Overview
• Management
• Board of Directors
• Advisory Boards
• Partner Collaborations
• Scientific & Research Collaborations
• Patients Overview
• Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• Understanding Primary CNS Lymphoma
• Compassionate Use Policy
• Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• TakeAim Lymphoma
• TakeAim Leukemia
• TakeAim CLL
• Pipeline Overview
• Emavusertib (CA-4948)
• Fimepinostat
• CA-170
• CA-327
• Overview
• Press Releases
• Events and Presentations
• Corporate Governance Committee Composition Contact the Board
• Financial Information SEC Filings Annual Reports IRS Form 8937
• Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage
• Contact Us
• Committee Composition
• Contact the Board
• SEC Filings
• Annual Reports
• IRS Form 8937
• Interactive Chart
• Historical Stock Lookup
• Analyst Coverage
• Life at Curis
• Open Positions
• Benefits

Frequently Asked Questions

What studies are sponsored by Duke Cancer Center?

Duke Cancer Center sponsors studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL.

What is Emavusertib?

Emavusertib (CA-4948) is one of the drugs in the pipeline at Duke Cancer Center.

How can I find financial information about Duke University?

Financial information about Duke University can be found in their SEC filings and annual reports.

What collaborations does Duke Cancer Center have?

Duke Cancer Center engages in partner collaborations and scientific research collaborations.

ShareAdd on Google
Tags: CRIS Viatris Investor Conferences Healthcare Duke University Cancer Center TakeAim Lymphoma TakeAim Leukemia
Last updated: Oct 23, 2024

Biotech snapshot

Cash runway
$5M liquidity · $3M/mo burn
~1 mo
High dilution risk
Lead asset
EmavusertibPhase 2
Chronic Lymphocytic Leukemia →